{"id":56755,"date":"2024-02-27T17:06:57","date_gmt":"2024-02-27T17:06:57","guid":{"rendered":"https:\/\/medsname.com\/divaa\/"},"modified":"2026-05-01T10:49:13","modified_gmt":"2026-05-01T10:49:13","slug":"divaa","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/divaa\/","title":{"rendered":"Divaa"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Divaa?<\/h3>\n<p style=\"margin:0;\"><strong>Divaa<\/strong> is een oraal <strong>tablet<\/strong> die <strong>divalproex sodium<\/strong> (250 mg, 500 mg) &mdash; a stable co-ordination compound of sodium valproate and valproic acid. Used for: <strong>multiple seizure types in epilepsy<\/strong> (generalised tonic-clonic, absence, myoclonic, partial), <strong>acute mania in bipolar I disorder<\/strong>, en <strong>migraineprofylaxe<\/strong>. Adult dosing: 600&ndash;2,500 mg\/day in 2&ndash;3 divided doses. Take with or after food to reduce GI upset. <strong>FDA Pregnancy Category X for migraine, Category D for epilepsy<\/strong> &mdash; one of the most teratogenic drugs in routine clinical use. Mandatory monitoring: baseline + periodic LFTs, FBC, ammonia if symptomatic. Common side effects: nausea, drowsiness, tremor, weight gain, hair thinning. Never stop abruptly &mdash; status epilepticus risk.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Wat u krijgt bij MedsBase:<\/strong> WHO-GMP gecertificeerde fabrikant \u00b7 Discrete verpakking \u00b7 Wereldwijde verzending \u00b7 1.400+ geverifieerde <a href=\"https:\/\/medsbase.com\/nl\/reviews\/\">klantbeoordelingen<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Elke bestelling is gedekt door onze <a href=\"https:\/\/medsbase.com\/nl\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n<h3>Waarom bestellen bij MedsBase<\/h3>\n<p>Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen \u2014 geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor \u2014 nooit \u201cMedsBase\u201d of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.<\/p>\n<h2 class=\"wp-block-heading\">What Is Divaa?<\/h2>\n<p>Divaa is an oral divalproex sodium <strong>tablet<\/strong> available in 250 mg, 500 mg strengths. Divalproex sodium is a 1:1 co-ordination compound of <strong>sodium valproate and valproic acid<\/strong> &mdash; in solution they dissociate to the same active species, but the compound formulation is more stable and somewhat better tolerated than plain sodium valproate. It is one of the broadest-spectrum anti-epileptic drugs in clinical use and is on the WHO Model List of Essential Medicines.<\/p>\n<p>Divaa is supplied by a WHO-GMP certified manufacturer and is bioequivalent to originator-brand divalproex (Depakote&reg;, AbbVie).<\/p>\n<h2 class=\"wp-block-heading\">How Does Divaa Work?<\/h2>\n<p>Valproate has multiple complementary mechanisms that together produce its broad-spectrum anti-seizure and mood-stabilising effects:<\/p>\n<ul>\n<li><strong>Blokkade van voltage-afhankelijke natriumkanalen<\/strong> &mdash; reduces high-frequency neuronal firing.<\/li>\n<li><strong>T-type calcium channel inhibition<\/strong> &mdash; particularly relevant to absence seizures.<\/li>\n<li><strong>GABAergic enhancement<\/strong> &mdash; raises brain GABA via inhibition of GABA-degrading enzymes.<\/li>\n<li><strong>NMDA receptor modulation<\/strong> &mdash; reduces glutamate excitatory transmission.<\/li>\n<li><strong>Histone deacetylase (HDAC) inhibition<\/strong> &mdash; epigenetic effects relevant to mood stabilisation.<\/li>\n<\/ul>\n<p>The combined effect is a wide therapeutic spectrum across seizure types, mood-stabilising activity in bipolar I disorder, and migraine prophylaxis through cortical-spreading-depression suppression.<\/p>\n<h2 class=\"wp-block-heading\">Toepassingen en Indicaties<\/h2>\n<ul>\n<li><strong>Epilepsy &mdash; generalised tonic-clonic seizures<\/strong> (first-line)<\/li>\n<li><strong>Epilepsy &mdash; absence seizures<\/strong> (first-line)<\/li>\n<li><strong>Epilepsy &mdash; myoclonic seizures<\/strong> (first-line for juvenile myoclonic epilepsy)<\/li>\n<li><strong>Epilepsy &mdash; partial (focal) seizures<\/strong> (with or without secondary generalisation)<\/li>\n<li><strong>Lennox-Gastaut-syndroom<\/strong> and other mixed seizure types<\/li>\n<li><strong>Bipolar I disorder &mdash; acute mania<\/strong> (FDA-approved monotherapy)<\/li>\n<li><strong>Bipolar I disorder &mdash; maintenance therapy<\/strong> (off-label, widely used)<\/li>\n<li><strong>Migraineprofylaxe<\/strong> in adults<\/li>\n<\/ul>\n<p>Divaa is <strong>niet<\/strong> first-line for: women of childbearing potential who could become pregnant (because of teratogenicity), or behavioural agitation in dementia (mortality signal in observational data).<\/p>\n<h2 class=\"wp-block-heading\">Divaa Dosage and How to Take<\/h2>\n<p>Divaa strengths: <strong>250 mg, 500 mg<\/strong>.<\/p>\n<p><strong>Standard adult dosing by indication:<\/strong><\/p>\n<ul>\n<li><strong>Epilepsy:<\/strong> Start 600 mg\/day (300 mg twice daily). Increase by 200 mg every 3 days. Maintenance 1,000&ndash;2,000 mg\/day in 2&ndash;3 doses. Maximum 2,500 mg\/day.<\/li>\n<li><strong>Bipolar I (acute mania):<\/strong> Start 750 mg\/day in divided doses; increase rapidly to serum level 50&ndash;125 &micro;g\/mL.<\/li>\n<li><strong>Migraineprofylaxe:<\/strong> Start 250 mg twice daily; increase to 500&ndash;1,000 mg\/day if needed.<\/li>\n<\/ul>\n<h3 class=\"wp-block-heading\">How to Take Divaa Properly<\/h3>\n<ol>\n<li><strong>Take with or after food.<\/strong> Empty-stomach dosing causes nausea in most patients.<\/li>\n<li><strong>Slik de tablet heel door met water.<\/strong> Do NOT crush or chew Divaa &mdash; this destroys the gradual-release coating and causes a dose dump.<\/li>\n<li><strong>Two to three times daily<\/strong> for immediate-release; CR\/ER versions allow once-daily or twice-daily dosing.<\/li>\n<li><strong>Be consistent with timing.<\/strong> Missed doses produce noticeable troughs.<\/li>\n<li><strong>Controleschema:<\/strong> baseline LFTs, FBC, platelet count, weight before starting. Repeat at 1 month, 3 months, 6 months, then annually. Check ammonia if drowsiness, confusion or vomiting develops.<\/li>\n<li><strong>Therapeutic drug monitoring:<\/strong> serum trough level &mdash; target 50&ndash;100 &micro;g\/mL (epilepsy), 50&ndash;125 &micro;g\/mL (bipolar). Not routinely needed for migraine.<\/li>\n<li><strong>Stop nooit abrupt.<\/strong> Sudden discontinuation in epilepsy can precipitate <strong>status epilepticus<\/strong>. Taper over 2&ndash;6 weeks under medical supervision.<\/li>\n<li><strong>Pregnancy prevention<\/strong> in women of childbearing potential: use reliable contraception throughout treatment. Discuss alternatives if pregnancy is a possibility.<\/li>\n<\/ol>\n<h2 class=\"wp-block-heading\">Side Effects of Divaa<\/h2>\n<p><strong>Vaak (dosisgerelateerd):<\/strong><\/p>\n<ul>\n<li>Nausea, vomiting, dyspepsia, abdominal pain<\/li>\n<li>Slaperigheid, vermoeidheid<\/li>\n<li>Tremor (fine, postural)<\/li>\n<li>Weight gain (10&ndash;20% gain &gt;5 kg)<\/li>\n<li>Hair thinning or hair loss (reversible)<\/li>\n<li>Diarree of obstipatie<\/li>\n<li>Increased appetite<\/li>\n<\/ul>\n<p><strong>Minder vaak maar belangrijk:<\/strong><\/p>\n<ul>\n<li>Thrombocytopenia (low platelet count)<\/li>\n<li>Hyperammonaemic encephalopathy &mdash; can occur with normal LFTs<\/li>\n<li>Polycystic ovary syndrome features in women<\/li>\n<li>Verhoogde leverenzymen<\/li>\n<li>Pancreatitis (rare but life-threatening)<\/li>\n<li>Cognitive slowing, memory difficulties<\/li>\n<\/ul>\n<p><strong>Zeldzaam maar zoek direct medische hulp:<\/strong><\/p>\n<ul>\n<li>Acute fulminant hepatic failure (especially children &lt;2 on polypharmacy)<\/li>\n<li>Acute pancreatitis<\/li>\n<li>Hyperammonaemic encephalopathy with normal LFTs<\/li>\n<li>Severe skin reactions (Stevens-Johnson syndrome, DRESS)<\/li>\n<li>Bone marrow suppression<\/li>\n<li>Severe bleeding from thrombocytopenia or platelet dysfunction<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Waarschuwingen en voorzorgsmaatregelen \u2014 KRITISCH<\/h2>\n<ul>\n<li><strong>Pregnancy: ABSOLUTE CONTRAINDICATION for migraine (Category X) and STRONG WARNING for epilepsy (Category D).<\/strong> Sodium valproate \/ divalproex is one of the most potent human teratogens in routine clinical use &mdash; ~10% major congenital malformations (neural tube defects, craniofacial defects, cardiac, hypospadias, limb defects) plus 30&ndash;40% risk of significant neurodevelopmental impairment (lower IQ, autism). Use only if no other option is effective. Reliable contraception is mandatory in women of childbearing potential.<\/li>\n<li><strong>Hepatotoxiciteit:<\/strong> highest risk in children &lt;2 on polypharmacy. Stop immediately for jaundice, severe vomiting, lethargy.<\/li>\n<li><strong>Pancreatitis:<\/strong> rare but life-threatening; idiosyncratic. Seek emergency care for severe abdominal pain.<\/li>\n<li><strong>Hyperammonemische encefalopathie<\/strong> &mdash; can occur with normal LFTs. Check ammonia if drowsiness, confusion or vomiting develops.<\/li>\n<li><strong>Mitochondrial disease (POLG mutations):<\/strong> absolute contraindication.<\/li>\n<li><strong>Urea cycle disorders:<\/strong> contraindication.<\/li>\n<li><strong>GI-bloedingrisico stijgt 2-4 keer; groot bloedingsrisico ~0,5-1%\/jaar bij monotherapie. Voeg PPI toe voor pati\u00ebnten met hoog GI-risico. De keuze van antistollings- en antiplaatjesmiddelen wordt individueel bepaald op basis van diagnose, bloedingsrisico, nierfunctie en geneesmiddelinteracties. Specialistische of huisartsbegeleiding is standaard.<\/strong> impairs platelet function. Tell the surgeon and stop 1&ndash;2 weeks before elective surgery if possible.<\/li>\n<li><strong>Dementia patients:<\/strong> off-label use no longer recommended &mdash; mortality signal.<\/li>\n<li><strong>Nooit abrupt stoppen<\/strong> in epilepsy &mdash; status epilepticus.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Contraindications &mdash; Who Should NOT Take Divaa<\/h2>\n<ul>\n<li>Pregnancy or planning pregnancy (especially for migraine prophylaxis)<\/li>\n<li>Known hypersensitivity to valproate<\/li>\n<li>Severe hepatic impairment or active liver disease<\/li>\n<li>Mitochondrial disease (POLG mutations)<\/li>\n<li>Urea cycle disorders<\/li>\n<li>Acute porphyria<\/li>\n<li>Children &lt;2 years (especially on polypharmacy &mdash; high hepatotoxicity risk)<\/li>\n<li>Active pancreatitis<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Geneesmiddelinteracties<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Combineren met<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Effect<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Wat te doen<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Lamotrigine<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Doubles lamotrigine levels &mdash; severe rash, SJS risk<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Halve lamotrigine starter dose; very slow titration. Specialist supervision.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Carbapenems (meropenem, ertapenem, imipenem)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Dramatically reduce valproate levels &mdash; precipitate seizures<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Vermijd combinatie.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Phenytoin, carbamazepine, phenobarbital<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Bidirectional interactions &mdash; unpredictable<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Monitor levels of both; specialist supervision.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Aspirin (high-dose), NSAIDs<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Displace valproate from albumin &mdash; increased free fraction<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Avoid high-dose aspirin. Monitor for valproate side effects.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Warfarine<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Increased anticoagulant effect plus platelet inhibition<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Monitor INR; watch for bleeding.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Topiramate<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Risk of hyperammonaemic encephalopathy<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Check ammonia if symptoms develop.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Alcohol<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Additive CNS depression and hepatotoxicity<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Limit alcohol entirely.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Gecombineerde orale anticonceptiva<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">No significant interaction<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">COCs remain effective. Reliable contraception is mandatory because of teratogenicity.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Benzodiazepines<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Additive CNS depression<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Avoid routine combination.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">Bewaaradvies<\/h2>\n<ul>\n<li>Bewaren bij kamertemperatuur, <strong>15\u201325\u00b0C<\/strong>. Protect from light and moisture.<\/li>\n<li>Bewaar tabletten in de originele blisterverpakking tot gebruik.<\/li>\n<li>Do not store in the bathroom.<\/li>\n<li>Keep out of reach of children &mdash; valproate is highly teratogenic; accidental ingestion by a pregnant household member is a serious risk.<\/li>\n<li>Gebruik niet na de vervaldatum.<\/li>\n<li>Breng ongebruikte tabletten terug naar een apotheek voor juiste verwijdering.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Gerelateerde alternatieven op MedsBase<\/h2>\n<p>Andere medicijnen op voorraad voor gerelateerde aandoeningen:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/nl\/neurological-conditions-and-epilepsy\/\">Bekijk alle neurologische &amp; epilepsiemedicijnen<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/anti-migraine\/\">Bekijk anti-migrainemiddelen<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/mental-health-and-psychiatric-medications\/\">Bekijk medicijnen voor geestelijke gezondheid &amp; psychiatrie<\/a><\/li>\n<\/ul>\n<h2 id=\"faqs\">Veelgestelde vragen<\/h2>\n<h3 class=\"wp-block-heading\">What is the difference between Divaa (divalproex) and sodium valproate?<\/h3>\n<p><strong>Pharmacologically essentially the same.<\/strong> Divalproex sodium is a 1:1 co-ordination compound of sodium valproate and valproic acid; in solution it dissociates to the same active species. The compound formulation is somewhat more stable and is reported to cause slightly less GI upset than plain sodium valproate, but the dose, monitoring, side-effect profile and pregnancy risk are identical. Most regulators and prescribers treat them interchangeably.<\/p>\n<h3 class=\"wp-block-heading\">Why is Divaa so dangerous in pregnancy?<\/h3>\n<p>Valproate is one of the most teratogenic drugs in routine clinical use. In-utero exposure carries approximately <strong>10% risk of major congenital malformations<\/strong> (neural tube defects, cardiac, craniofacial, hypospadias, limb defects) plus <strong>30&ndash;40% risk of significant neurodevelopmental impairment<\/strong> (lower IQ, autism spectrum disorder). For migraine prophylaxis the FDA classifies it as <strong>Category X (absolute contraindication)<\/strong>; for epilepsy Category D. Women of childbearing potential need explicit counselling, reliable contraception throughout, and 5 mg\/day folate before any planned pregnancy.<\/p>\n<h3 class=\"wp-block-heading\">Why must I never stop Divaa abruptly?<\/h3>\n<p>In epilepsy, sudden discontinuation can precipitate <strong>status epilepticus<\/strong> &mdash; a medical emergency, with significant mortality if untreated. This can happen even after years of stability. Taper over 2&ndash;6 weeks under medical supervision. The same caution applies to bipolar maintenance &mdash; abrupt cessation can precipitate manic relapse.<\/p>\n<h3 class=\"wp-block-heading\">What blood tests do I need on Divaa?<\/h3>\n<p><strong>Before starting:<\/strong> liver function (AST, ALT, GGT), full blood count including platelets, baseline weight, fasting glucose. <strong>Tijdens behandeling:<\/strong> repeat at 1 month, 3 months, 6 months, then annually. <strong>If unwell:<\/strong> ammonia level if any drowsiness, confusion, vomiting. Periodic serum valproate trough level for epilepsy (target 50&ndash;100 &micro;g\/mL).<\/p>\n<h3 class=\"wp-block-heading\">Will Divaa cause weight gain or hair loss?<\/h3>\n<p>Both are common. <strong>Gewichtstoename<\/strong> affects 10&ndash;20% of patients (5&ndash;10 kg over the first 6&ndash;12 months). <strong>Hair thinning<\/strong> affects up to 10% of patients, usually starts in the first 3&ndash;6 months, and is reversible on dose reduction or discontinuation. Zinc and selenium supplementation is sometimes used (limited evidence).<\/p>\n<h3 class=\"wp-block-heading\">Can Divaa be used with lamotrigine?<\/h3>\n<p>Yes but with extreme caution. Valproate <strong>doubles lamotrigine levels<\/strong>, sharply increasing the risk of severe rash and Stevens-Johnson syndrome. The combination is sometimes used but lamotrigine must be started at <strong>half the usual dose<\/strong> with a much slower up-titration. Specialist supervision is essential.<\/p>\n<h3 class=\"wp-block-heading\">Why do certain antibiotics interact dangerously with Divaa?<\/h3>\n<p>Carbapenem antibiotics (meropenem, ertapenem, imipenem) <strong>dramatically reduce valproate levels<\/strong> &mdash; sometimes &gt;90% within 1&ndash;3 days &mdash; through a poorly understood mechanism that may involve enterohepatic recirculation. The result is sudden loss of seizure control. <strong>Avoid this combination.<\/strong> If a patient on valproate needs a carbapenem, switch the antibiotic.<\/p>\n<h3 class=\"wp-block-heading\">Can Divaa cause polycystic ovary syndrome?<\/h3>\n<p>Long-term valproate in women is associated with features of polycystic ovary syndrome &mdash; menstrual irregularity, hyperandrogenism (acne, hirsutism), weight gain and ovarian cysts. The risk is higher with long-duration use and higher doses. If PCOS features develop, alternative anticonvulsants (lamotrigine, levetiracetam) should be considered.<\/p>\n<h3 class=\"wp-block-heading\">Can I drink alcohol on Divaa?<\/h3>\n<p>Light, occasional alcohol is usually tolerated, but combination is additive: more sedation, more hepatic stress. Heavy drinking sharply increases liver toxicity and should be avoided.<\/p>\n<h3 class=\"wp-block-heading\">How do I taper off Divaa safely?<\/h3>\n<p>Reduce by 200&ndash;500 mg every 2 weeks under your neurologist&#8217;s or psychiatrist&#8217;s supervision. Faster tapers risk seizure rebound (epilepsy) or manic relapse (bipolar). Sudden discontinuation is reserved for serious adverse reactions (severe pancreatitis, fulminant hepatic failure).<\/p>\n<h3 class=\"wp-block-heading\">Where is Divaa manufactured?<\/h3>\n<p>Divaa is supplied by a <strong>WHO-GMP gecertificeerde fabrikant<\/strong> and is bioequivalent to originator-brand divalproex (Depakote&reg;). Batch certificates of analysis are available on request.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Gerelateerde alternatieven<\/h3>\n<p>Andere producten in <strong>Chronische aandoeningen<\/strong> die klanten ook bekijken:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/nl\/app-up\/\">App-Up<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/ciclohale\/\">Ciclohale<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/mesacol\/\">Mesacol<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/venish-sr\/\">Venish SR<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/taficita\/\">Taficita<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Manages Seizures<br \/>\n\u2705 Treats Bipolar Disorder<br \/>\n\u2705 Mood Stabilization<br \/>\n\u2705 Prevents Migraines<br \/>\n\u2705 Prescribed by Physicians<\/p>\n<p>Divaa contains Divalproex Sodium IP.<\/p>","protected":false},"featured_media":56756,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3468],"product_tag":[4166,4167],"class_list":{"0":"post-56755","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-neurological-conditions-and-epilepsy","9":"product_tag-divaa","10":"product_tag-divalproex-sodium-ip","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product\/56755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/comments?post=56755"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/media\/56756"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/media?parent=56755"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_brand?post=56755"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_cat?post=56755"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_tag?post=56755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}